AVAX Currently Pending Clinical Trials News for its Pipeline (OTC:AVXT.PK)

AVAX Technologies, Inc. has gone through a vast number of ups and downs throughout 2006 to 2007. At this time StocksHaven Investments profiles the company and takes look at what investors may expect within the near future.

AVAX had a number of expectations to meet in order to sustain ongoing business operations: equity financing, FDA registration for phase II and phase III clinical trials, and collaborations and expactions.The successful completion of these goals has paved the way for a fresh and optimistic 2008 and 2009 for AVAX.

Having raised $10M in equity financing, and $1.2M in a collaboration of CTCA on the OVARIAN trials (Ovax), dilution should be out of the question for the remainder of 2010. Despite all of this, there remains one main reason which makes AVAX a solid company: their pipeline which targets some of the fastest growing markets within the biotech medical industry.

MVax is aiming towards a $775M Melanoma treatment market by 2010, while Ovax looks to enter a potential Ovarian cancer drug market of $1.6B by 2016. Moreover, AVAX’ currently trades at a highly undervalued estimated market cap of 27.10M when compared to a similar cancer treatment company in Cell Therapeutics (NASDAQ:CTIC), which is sitting at roughly 627.11M market cap without any drugs currently being approved by the FDA. 2010 should prove to be an eventful year for this up and coming rising small cap biotech.

MVax® is AVAX’s lead product candidate and it is currently in an International Phase III Registration trial with centers in the U.S., Europe and Israel. To date over 600 patients have been treated with the AC Vaccine Technology.

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is an internationally integrated biotechnology company focused on developing and commercializing its AC Vaccine® technology for the treatment of cancer. The AC Vaccine Technology is an immunotherapeutic treatment that educates the patient’s immune system to recognize cancer cells as foreign through the process of haptenization. Haptenization is a re-education of the immune system through a chemical modification of antigens on the cancer cell which allows for the development of an immune response to cancer cells that were previously ignored by the immune system. To produce AVAX’s AC Vaccine cancer cells are obtained from tumors excised during routine surgery. These cells are then treated with the hapten dinitrophenyl (DNP). Injection of the DNP-modified vaccine induces an immune response against native cancer cells in the patient’s body, and, under the best of circumstances, kills them or controls their growth.

AVAX is headquartered in Philadelphia, PA with operations in Lyon, France where it has established a cGMP manufacturing facility that is currently producing the vaccines for the ongoing Phase III Registration trial of MVax®, the AC Vaccine for Melanoma.

The full special report on the company appears today at http://www.stockshaven.com/avax-currently-pending-clinical-trials-news-for-its-pipeline-otcavxt-pk/

Disclosure: Long AVXT.PK

To feature a publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at michaelvlaicu@stockshaven.com or visit http://www.stockshaven.com/ir_contract/ for more info

###

About StocksHaven Investments

StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.

For more financial and investment news, visit www.StocksHaven.com

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

Contact Information

Michael Vlaicu

Founder and Lead Investment Analyst

StocksHaven Investments

Contact via E-mail